Combination therapy including sapc-dops for the treatment of pancreatic cancer
AssigneesBexion Pharmaceuticals Inc., University of Cincinnati
InventorsXiaoyang Qi, Olugbenga Olowokure, Ray Takigiku
Life of this patent
Estimating the term…
Loading patent…
AssigneesBexion Pharmaceuticals Inc., University of Cincinnati
InventorsXiaoyang Qi, Olugbenga Olowokure, Ray Takigiku
Estimating the term…
Disclosed herein, according to the present invention, are methods of treating pancreatic cancer comprising administering a first pharmaceutical composition comprising Saposin C and dioleoylphosphatidylserine (SapC-DOPS) and administering a second pharmaceutical composition comprising an anti-neoplastic agent. Optionally, additional pharmaceutical compositions may be administered. Also disclosed are methods of inhibiting tumor growth. Also disclosed are kits for the treatment of pancreatic cancer comprising at least two pharmaceutical compositions, wherein a first pharmaceutical composition comprises SapC-DOPS and wherein a second pharmaceutical composition comprises a first antineoplastic agent. Also disclosed herein are combination therapeutics comprising a first pharmaceutical composition comprising SapC-DOPS and at least a second pharmaceutical composition comprising an antineoplastic agent, wherein the first and second pharmaceutical compositions are formulated separately to be used in the form of a kit where they are present together.
A method of treating pancreatic cancer comprising administering a first pharmaceutical composition comprising Saposin C and dioleoylphosphatidylserine (SapC-DOPS) and administering a second pharmaceutical composition comprising an antineoplastic agent.
A method of inhibiting tumor growth comprising administering a first pharmaceutical composition comprising SapC-DOPS and administering a second pharmaceutical composition comprising an antineoplastic agent.
A kit for the treatment of pancreatic cancer comprising at least two pharmaceutical compositions, wherein a first pharmaceutical composition comprises SapC-DOPS and wherein a second pharmaceutical composition comprises a first antineoplastic agent.
A combination therapeutic comprising a first pharmaceutical composition comprising SapC-DOPS and a second pharmaceutical composition comprising at least one antineoplastic agent, wherein the first and the second pharmaceutical compositions are formulated separately to be used in the form of a kit where they are present together.
Dependencies are inferred from the claim text.